Noam Y Kirson

Summary

Affiliation: Analysis Group
Country: USA

Publications

  1. doi request reprint Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA, USA
    Curr Med Res Opin 27:1763-8. 2011
  2. doi request reprint Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs
    Noam Y Kirson
    Analysis Group, Inc, 111 Huntington Ave, 10th Fl, Boston, MA 02199, USA
    J Clin Psychiatry 74:568-75. 2013
  3. doi request reprint Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 16:479-89. 2013
  4. doi request reprint Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 15:87-95. 2012
  5. doi request reprint Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 13:482-91. 2010
  6. doi request reprint Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 13:472-81. 2010
  7. doi request reprint Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA, USA
    Appl Health Econ Health Policy 9:377-87. 2011
  8. doi request reprint The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals
    Noam Y Kirson
    Analysis Group, Inc, Boston, Massachusetts
    Pain Med 16:1325-32. 2015
  9. ncbi request reprint Characteristics of High-Cost Patients Diagnosed with Opioid Abuse
    Amie Shei
    Analysis Group, 111 Huntington Ave, Tenth Fl, Boston, MA 02199
    J Manag Care Spec Pharm 21:902-12. 2015
  10. doi request reprint Sources of prescription opioids among diagnosed opioid abusers
    Amie Shei
    Analysis Group Inc, Boston, MA, USA
    Curr Med Res Opin 31:779-84. 2015

Collaborators

Detail Information

Publications15

  1. doi request reprint Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA, USA
    Curr Med Res Opin 27:1763-8. 2011
    ..The prevalence of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in the US is largely unknown. Prior research has estimated PAH prevalence in Europe at ∼15-52 per million...
  2. doi request reprint Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs
    Noam Y Kirson
    Analysis Group, Inc, 111 Huntington Ave, 10th Fl, Boston, MA 02199, USA
    J Clin Psychiatry 74:568-75. 2013
    ..The optimal use of different antipsychotic formulations in a general clinical setting depends on better understanding of the underlying reasons for differences in effectiveness across research designs...
  3. doi request reprint Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 16:479-89. 2013
    ..No head-to-head trial has compared the efficacy of adalimumab vs etanercept and infliximab for psoriatic arthritis (PsA). This study implements a matching-adjusted indirect comparison technique to address that gap...
  4. doi request reprint Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 15:87-95. 2012
    ..Compare direct and indirect costs of oxymorphone extended-release ('oxymorphone') and oxycodone controlled-release ('oxycodone') users...
  5. doi request reprint Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 13:482-91. 2010
    ..To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin...
  6. doi request reprint Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA 02199, USA
    J Med Econ 13:472-81. 2010
    ..Repeat comparison for the subset of patients treated in long-term care (LTC) settings...
  7. doi request reprint Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA, USA
    Appl Health Econ Health Policy 9:377-87. 2011
    ..Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially fatal disease. Little is known about the economic burden associated with CTEPH patients in the US...
  8. doi request reprint The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals
    Noam Y Kirson
    Analysis Group, Inc, Boston, Massachusetts
    Pain Med 16:1325-32. 2015
    ..Estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially insured individuals...
  9. ncbi request reprint Characteristics of High-Cost Patients Diagnosed with Opioid Abuse
    Amie Shei
    Analysis Group, 111 Huntington Ave, Tenth Fl, Boston, MA 02199
    J Manag Care Spec Pharm 21:902-12. 2015
    ..A subset of patients diagnosed with opioid abuse has disproportionately high health care costs, but little is known about the characteristics of these patients. ..
  10. doi request reprint Sources of prescription opioids among diagnosed opioid abusers
    Amie Shei
    Analysis Group Inc, Boston, MA, USA
    Curr Med Res Opin 31:779-84. 2015
    ..Diversion and abuse of prescription opioids are important public health concerns in the US. This study examined possible sources of prescription opioids among patients diagnosed with opioid abuse...
  11. doi request reprint Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population
    Noam Y Kirson
    Analysis Group, Inc, Boston, MA, USA
    Appl Health Econ Health Policy 9:293-303. 2011
    ..Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US...
  12. doi request reprint The economic burden of diagnosed opioid abuse among commercially insured individuals
    J Bradford Rice
    Manager, Analysis Group, Inc, Boston, MA
    Postgrad Med 126:53-8. 2014
    ....
  13. doi request reprint Medical resource use and costs among pain patients with potential opioid-tolerability issues
    Noam Y Kirson
    Manager, Analysis Group, Inc, Boston, Massachusetts
    J Opioid Manag 10:305-10. 2014
    ..To estimate excess medical resource use and costs associated with prescription opioid (RxO) tolerability issues...
  14. pmc Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data
    J Bradford Rice
    Analysis Group, Inc, 111 Huntington Avenue, 10th Floor, Boston, MA, 02199, USA
    Appl Health Econ Health Policy 12:435-46. 2014
    ....
  15. doi request reprint Use of prescription opioids with abuse-deterrent technology to address opioid abuse
    Edward Michna
    Brigham and Women s Hospital, Chestnut Hill, MA, USA
    Curr Med Res Opin 30:1589-98. 2014
    ..This study examined the degree to which some patients may avoid switching to reformulated ER opioids with abuse-deterrent technology and the extent to which those patients are more likely to be abusers...